Uncontrolled Type 2 Diabetes Mellitus
Conditions
Brief summary
This trial is a Phase-III, Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled clinical trial to determine the efficacy, safety, and tolerability of oral CPL-2009-0031 140 mg in comparison with Sitagliptin 100 mg in patients with Uncontrolled Type-2 Diabetes Mellitus (T2DM).
Detailed description
In this phase-III trial, after due consent and completing initial 2-weeks of placebo run-in period with diet, exercise and counseling, eligible patients with uncontrolled T2DM will be randomized in balance to receive either once daily oral CPL-2009-0031 140 mg or Sitagliptin 100 mg. After completing 12 weeks of study post-randomization for regulatory submission, patients will be instructed for continuation of extension phase of treatment and follow up upto 36 weeks. HbA1c will be measured at screening, baseline, 12 weeks, 24 weeks and 36 weeks of treatment. While, Fasting Blood Sugar (FBS) and Postprandial Blood Sugar (PPBS) measurement will be performed every 2 weeks. The enrolled patients will be monitored for safety (AE and SAE) throughout the study period.
Interventions
DRUGCPL-2009-0031 140 mg
Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.
Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.
Sponsors
New Millennium Indian Technology Leadership Initiative (NMITLI) program of Council of Scientific and Industrial Research, India
Cadila Pharnmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Investigator, patient, study staff, data monitors and database personnel will be blinded to the study treatment.
Intervention model description
Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled study
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Male and female adult patient of 18-65 years with uncontrolled type 2 diabetes Mellitus (T2DM). * Patients with HbA1c ≥ 7 to 10 and those on oral hypoglycemic agents ≤ 2 other than Insulin and Gliptins. * BMI in the range of 18.5 - 35 kg/m2. * All patients must be willing to give informed consent and can understand & complying protocol requirement. * Patients who are in good health at the time of entry into the study as determined by medical, medication and hypersensitivity histories, clinical examination, vital sign measurements, chest X-ray, 12-lead ECG measurement and clinical judgment of the investigator. * Documented negative test for human immuno virus (HIV), Hepatitis B surface antigen (HBsAg) and Hepatitis C virus (HCV).
Exclusion criteria
* Those who are on insulin and not ready for wash out of 3 months. * Those who are on gliptin and not ready for wash out of 3 months. * Those with a history of severe ketosis, diabetic coma or pre-coma, or type 1 diabetes. * Those scheduled for or who had undergone surgery. * Those with a severe infection or serious injury * Pregnant and lactating women. * Hypersensitivity and contraindication to DPP-IV inhibitors or excipients of investigational drug formulation. * Hypertensive patients with blood pressure ≥160/100 mm of Hg. * History of ischemic heart disease (as evident from ECG), stroke and/or transient ischemic attack. * Debilitating neurological or psychiatric disorders * History or currently consuming abusing drugs or alcohol. * Serious hepatic or renal impairment (liver dysfunction as evidenced by SGPT/SGOT level of 2.5 X ULN and renal dysfunction as evidenced by creatinine level 2.5 X ULN). * Patient with abnormal clinical chemistry, hematology or urinalysis results that are considered clinically significant by the investigator or the sponsor. * Patient has any concurrent illness which, in the opinion of the investigator or coinvestigator, may interfere with treatment or evaluation of safety or completion of this study. * In the investigator's judgment, the patient is unable to adhere to the treatment regimen, protocol procedures or study requirements. * Participation in another clinical trial in the past 3 months. * Patients with history of smoking or currently having smoking habit will not be included in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in HbA1c level | Baseline, 12 weeks, 24 weeks and 36 weeks from onset of therapy | To evaluate HbA1c levels between oral CPL-2009-0031 140 mg and oral Sitagliptin 100 mg |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fasting Blood Sugar (FBS) level | Every 2 week till 12 weeks and every 4 weeks between 12 weeks to 36 weeks from onset of therapy | To compare Fasting Blood Sugar between oral CPL-2009-0031 140 mg and oral Sitagliptin 100 mg |
| Postprandial Blood Sugar (PPBS) level | Every 2 week till 12 weeks and every 4 weeks between 12 weeks to 36 weeks from onset of therapy | To compare Fasting Blood Sugar between oral CPL-2009-0031 140 mg and oral Sitagliptin 100 mg |
| Frequency of Serious Adverse Events | From randomization to end of 12 week, 24 week and 36-weeks therapy | Determination of safety and tolerability of CPL-2009-0031 140 mg versus Sitagliptin 100 mg based on Frequency of serious adverse events |
| Number of hypoglycemic events | From randomization to end of 12 week, 24 week and 36-weeks therapy | Determine number and severity of hypoglycemic events of CPL-2009-0031 140 mg versus Sitagliptin 100 mg |
| Frequency of adverse events | From randomization to end of 12 week, 24 week and 36-weeks therapy | Determine frequency and severity of adverse events of CPL-2009-0031 140 mg versus Sitagliptin 100 mg |
Countries
India
Outcome results
None listed